Article Type

Original Study


Objectives: To evaluate the efficacy of propranolol as a safe andeffectiveline of treatment of differentheadand neck infantile hemangiomas.Patients and methods: 13 casesof head and neck infantile hemangiomaswith different localities. Propranololis started at 0.5 mg/kg/d in3divided doses for the first week.Then, the dose was increased tobe1 mg/kg/d in 3 divided doses forthesecond week and finally doubledtobe 2 mg/kg/d in 3 divided doseswhichis the maintenance dose continuedtill the response become stationaryin the form of achieving themaximum regression of the lesionortill reaching the involution phase Results: Twelve cases showed noserious adverse effects of propranolol.Their mean age at the presentationwas 9.33 (range 2 – 22) months;theirmean duration of administrationofthe drug at the maintenance dosewas6 (range 2 – 10) months andtheirmean follow up period after thestoppageof the drug was 7.23(range5 – 9) months. Only one caseexperiencedrecurrent attacks ofasthmatiformbronchitis after 8weeksof starting the treatment withveryminimal regression of the lesionanddid not complete the regimen.Twelvecases showed clinical improvementof the lesion in the formofreduction of the size of the lesionandchange of the color from intense red to purple with one of them developedre-growth of the lesion afterstoppageof the treatment by 4monthslater. No improvement wasreportedin one case.Conclusion: Propranolol in a doseof 2 mg/kg/d in 3 divided doses is avaluable line of treatment of differenthead and neck infantile hemangiomaswith safe profile.

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.